News Celgene to file potential MS blockbuster this year Success with ozanimod would justify $7.2 billion outlay for Receptos.
News Valeant's Siliq approved but suicidal thoughts warning will ... But drug will have boxed warning over suicidal ideation.
News Trump demands cuts to 'astronomical' drug prices - but pharm... Trump calls pharma leaders to White House to discuss cutting taxes, regulations - and drug prices
News Delinia adds to Celgene's immunology ambitions Celgene continues with focus on autoimmune diseases.
News Celgene broadens immunology presence with Anokion deal Biotech specialises in autoimmune disorder drugs.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
